
|Videos|July 21, 2023
Key Retreatment Decisions in the Clinical Trials for Faricimab in nAMD
Author(s)Varun Chaudhary, MD, FRCS(C)
Dr Varun Chaudhary presents the retreatment decisions during the treat-and-extend phase of the TENAYA and LUCERNE clinical trials in neovascular AMD, focusing on the percentage of patients who maintained, extended, or reduced their treatment interval based on visual and anatomic criteria.
Advertisement
Episodes in this series
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retina Society 2026: MCO-010 optogenetic therapy maintains visual acuity gains through 4 years in advanced RP
2
Manju Subramanian, MD: anti-VEGF linked to kidney function decline
3
Retina Society 2026: Medium-dose OCU410 gene therapy cuts geographic atrophy progression by up to 32% in phase 2 trial
4
Retina Society 2026: Could statins reduce PVR risk after RD repair?
5














